MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong revenue growth and improved gross margins are offset by increased net losses and significant financial obligations. The absence of a share repurchase program and concerns over sustaining growth in a competitive market further temper positive sentiment. While management's optimistic guidance and effective market strategy are promising, the lack of specific guidance and financial challenges maintain a neutral outlook for the stock price in the near term.
Key Financial Performance
Revenue $24.3 million, an increase of 22% from $19.8 million in Q1 2024.
Gross Profit $15.5 million, an increase of 29% from $12.1 million in Q1 2024.
Gross Margin 63.8%, an increase of 3 percentage points from 60.8% in Q1 2024, primarily attributed to test mix.
Operating Loss $4.6 million, a decline of 31% from $6.6 million in Q1 2024, driven by growth in sales and gross profit.
Net Loss $9.2 million, an increase of 8% from $8.5 million in Q1 2024, primarily due to non-cash fair value adjustments of $2.5 million.
Adjusted EBITDA Negative $1.3 million, a 71% improvement from negative $4.5 million in Q1 2024.
Cash and Cash Equivalents $65.7 million as of March 31, 2025, with a pro forma cash balance of $37.7 million after the $28 million earn-out payment.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Tissue-based tests revenue growth: Tissue-based test volume grew 41% for the quarter, with approximately 12,600 tests conducted, accounting for 85% of Q1 revenue.
GPS test acquisition: MDxHealth acquired the GPS test from Exact Sciences in 2022, aiming to leverage its sales channel and pathology access to accelerate revenue and gross margin.
Market opportunity for Confirm test: The Confirm test addresses limitations of needle biopsy, with a significant market opportunity estimated at $500 million.
Prostate cancer market growth: The rate of prostate cancer is rising an estimated 5% to 10% annually, indicating a growing market for MDxHealth's tests.
Revenue growth: Q1 2025 revenue increased by 22% to $24.3 million, marking the 16th consecutive quarter of 20% or greater revenue growth.
Gross profit increase: Gross profit for Q1 was $15.5 million, a 29% increase compared to the prior year, with gross margins improving to 63.8%.
Sales channel efficiency: MDxHealth has not expanded its sales organization but continues to generate leverage from its existing sales channel, achieving growth without additional investment.
Revenue guidance: The company confirmed its revenue guidance for 2025 at $108 million to $110 million, maintaining its goal of 20% revenue growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Growth Risks: Despite achieving 22% revenue growth in Q1 2025, the company faces risks related to sustaining this growth rate in a competitive market, particularly as they aim for 20% or greater revenue growth in 2025 and beyond.
Competitive Pressures: MDxHealth operates in a competitive landscape for prostate cancer diagnostics, particularly with the GPS test, where there are two competitors. The company must continuously innovate and maintain its market share to mitigate risks associated with competition.
Regulatory Issues: The company operates in a highly regulated industry, and any changes in regulations or compliance requirements could pose risks to their operations and market access.
Supply Chain Challenges: While the company has not reported immediate supply chain issues, the potential for disruptions exists, which could impact their ability to deliver tests and services.
Economic Factors: Economic conditions, including potential impacts from tariffs, could affect the company's financial operations and overall market environment.
Financial Obligations: The recent $28 million earn-out payment to Exact Sciences could strain cash reserves, reducing financial flexibility and increasing operational risk.
Operating Losses: The company reported an operating loss of $4.6 million, which, while improved, indicates ongoing financial challenges that could affect future investments and growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth Goal: MDxHealth aims for 20% or greater revenue growth in 2025 and beyond.
Q1 Revenue Growth: Achieved Q1 revenue growth of 22%, marking the 16th consecutive quarter of 20% or greater revenue growth.
Test Volume Growth: Tissue-based test volume grew 41% in Q1 2025.
Market Opportunity for Confirm Test: The market opportunity for the Confirm test is estimated at $500 million, with a focus on addressing false negatives in prostate biopsies.
GPS Test Value Proposition: The GPS test provides actionable diagnostic answers for both positive and negative patient profiles, with a compelling value proposition for urologists.
2025 Revenue Guidance: Confirmed revenue guidance of $108 million to $110 million for 2025, meeting or exceeding the 20% revenue growth goal.
Adjusted EBITDA Outlook: Expecting to achieve positive adjusted EBITDA in Q2 2025.
Cash Position: Cash and cash equivalents as of March 31, 2025, were $65.7 million, with a pro forma cash balance of $37.7 million after earn-out payment.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: None
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is resonating with pathologists now compared to a year ago?
A:Management noted that the misconception that pathology would be reluctant to adopt their test due to missed reads on biopsies has been dismissed. They emphasized the importance of the two-part value of their tissue-based test, Confirm, and the lower tissue requirement for their GPS test, which aligns with pathologists' desire to preserve tissue.
Q:What are customers saying about the key reasons for taking market share?
A:Management indicated that the entire story contributes to market share gains, including the quality of their sales reps, the consultative approach, and the unique value proposition of their tests, particularly in avoiding repeat biopsies.
Q:What impacts did weather and fewer sales days have on Q1 performance?
A:Management stated that they did not see significant impacts from weather or fewer sales days, and they expect continued execution in Q2 without providing specific guidance.
Q:Can you comment on the growth of Confirm and GPS tests?
A:Management mentioned balanced growth between Confirm and GPS, indicating that both tests are seeing adoption and that their sales strategy is effective.
Q:What is your outlook on M&A opportunities?
A:Management expressed a disciplined approach to M&A, indicating they are looking for growth opportunities but are cautious due to regulatory and reimbursement challenges.
Q:What is the current penetration of your tests among urologists?
A:Management did not provide specific numbers but indicated that their penetration among urologists is strong and that their sales strategy is effectively driving adoption.
Q:What is the outlook for pricing and gross margins?
A:Management indicated that they expect to hold or advance average selling prices (ASPs) and that gross margins will improve as the mix shifts towards tissue-based tests.
Q:What are the key milestones for the company going forward?
A:Management emphasized continued top-line growth, disciplined OpEx management, and the potential for additional growth opportunities.
Q:Review of Unclear Management Responses
A:Management avoided quantifying the current market share of GPS and Confirm tests, stating that they are in a good position but refraining from providing specific numbers. Additionally, they did not provide a clear view on the exact percentage of revenues generated from large urology group practices.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Executive
Confirm
Exact Sciences
Executive Officer
Fraunces LifeSci
GPS test
LifeSci Advisors
Officer Chief
biopsy value
cancer quality
care
clinician
commitment
core biopsy
earn payment
excellence
gene
group
limitation
market opportunity
mdx
measure
patient feature
patient value
population
repeat biopsy
success
talent
test value
test volume
thesis
today Chief
track goal
tumor tissue
urologist
value adjustment
value test
MDXH Transcript
MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals several concerning factors: a widening operating loss, a significant net loss, and a decrease in cash reserves. Although management expressed confidence in their core business and provided optimistic guidance, the Q&A highlighted unresolved financial issues and vague responses from management. These factors, combined with the absence of strong positive catalysts, suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8% over the next two weeks.
MDxHealth SA (MDXH) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture. Positive elements include revenue growth, improved gross margins, and strategic plans for sales expansion and operational efficiency. However, concerns arise from increased operating losses, complex integration of ExoDx, and lack of specific guidance details. Q&A insights highlight management's confidence in growth but also reveal uncertainties in achieving financial targets. The market may react cautiously, balancing optimism about strategic initiatives with concerns over financial health and execution risks. Given these factors, a neutral stock price movement is anticipated.
MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript
Positive11-12
The earnings call presents a generally positive outlook, with a notable decrease in operating and net losses, and strong cash reserves. The Q&A highlights confidence in Exo's future contributions and sustained performance in GPS and Confirm products. Despite some avoidance in addressing ASP declines, the strategic focus on Exo and sales team expansion suggests growth potential. The absence of material negative factors and optimistic guidance point towards a positive stock price movement in the near term.
MDxHealth SA (MDXH) Q1 2025 Earnings Call Transcript
Unknown5-14
The earnings call presents a mixed picture: strong revenue growth and improved gross margins are offset by increased net losses and significant financial obligations. The absence of a share repurchase program and concerns over sustaining growth in a competitive market further temper positive sentiment. While management's optimistic guidance and effective market strategy are promising, the lack of specific guidance and financial challenges maintain a neutral outlook for the stock price in the near term.
MDXH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
